S*BIO Pte Ltd
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From S*BIO Pte Ltd
'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
Sanofi kills PhIII JAK2 inhibitor on safety grounds
Sanofi has called an immediate halt to all trials of fedratinib (SAR302503) following reports of neurological side-effects. The company had reported positive Phase III results for the JAK2 inhibitor in myelofibrosis earlier this year. Now, however, it says it is cancelling all plans for regulatory filings.
Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.
Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner
Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice